Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

This is a multi-center, randomized controlled, prospective clinical study.

Trial Details

NCT ID
NCT07248956
Phase
PHASE2
Sponsor
Eye & ENT Hospital of Fudan University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Finolizumab
  • Albumin-Bound Paclitaxel /nab-Paclitaxel
  • Cisplatin
  • Definitive radiotherapy
  • Surgery with postoperative radiotherapy or chemoradiotherapy.
Locations (sample)
  • Harbin, Heilongjiang, China|45.75,126.65
  • Jinan, Shandong, China|36.66833,116.99722
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Willingness to provide written informed consent;
  • Age ≥18 and ≤75 years;
  • Treatment-naïve for malignant disease;
  • Resectable stage III-IVA hypopharyngeal carcinoma with response of PR ≥ 50% after neoadjuvant therapy according to RECIST 1.1 ;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →